Mehrdad Mobasher, M.D., M.P.H.

Mehrdad Mobasher, M.D., M.P.H., joined the company in August 2022 as Chief Medical Officer for Hematology. Prior to joining BeiGene, Dr. Mobasher served as Senior Vice President and Global Head of Late-Stage Oncology Development at Zai Lab, responsible for the entire late-stage oncology portfolio. Prior to Zai Lab, he was the Chief Medical Officer at Corvus Pharmaceuticals, where he led the pipeline development in solid tumors, COVID-19, and T-cell lymphomas. Previously, Mehrdad spent about nine years at Roche/Genentech in a variety of leadership roles, including Group Medical Director and venetoclax Development Lead across all indications.

Mehrdad was also an adjunct clinical faculty member in the Division of Medical Oncology at Stanford University after finishing his post-doctoral fellowships in hematology and medical oncology there. He received an M.D. from Tehran University of Medical Sciences in Iran, and an M.P.H. in general epidemiology from the School of Public Health at the University of Michigan. He completed an internship and residency in internal medicine at the University of California, Irvine Medical Center.